Similarly, PPP1R1B has been shown to interfere with the response to molecular targeted therapy in EGFR-mutated LUAD [70], and SHP2 has been associated with MET-mutated NSCLC [71]. This evidence concerns the gene PPP1R1B and non-small cell lung carcinoma.